Page last updated: 2024-10-30

mesalamine and Atherogenesis

mesalamine has been researched along with Atherogenesis in 2 studies

Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cappello, M1
Licata, A1
Calvaruso, V1
Bravatà, I1
Aiello, A1
Torres, D1
Della Corte, V1
Tuttolomondo, A1
Perticone, M1
Licata, G1
Craxì, A1
Cammà, C1
Rungoe, C1
Basit, S1
Ranthe, MF1
Wohlfahrt, J1
Langholz, E1
Jess, T1

Other Studies

2 other studies available for mesalamine and Atherogenesis

ArticleYear
Increased expression of markers of early atherosclerosis in patients with inflammatory bowel disease.
    European journal of internal medicine, 2017, Volume: 37

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Atherosclerosis; Biomarkers; Carotid Arteries; Carot

2017
Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study.
    Gut, 2013, Volume: 62, Issue:5

    Topics: Adolescent; Adult; Aged; Atherosclerosis; Case-Control Studies; Cohort Studies; Denmark; Female; Fol

2013